stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Total debt
NeoGenomics, Inc.'s total debt at the end of fiscal 2025 was $341.9M, down 36.8% from $541.1M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $378.8M. Over the past ten years it has ranged from $66.8M (fiscal 2015) to $542.3M (fiscal 2022); the current reading is higher than 64% of that period. NeoGenomics, Inc. ranks 18th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $341.9M | (36.82%) |
| FY2024 | $541.1M | 0.54% |
| FY2023 | $538.2M | (0.76%) |
| FY2022 | $542.3M | 0.34% |
| FY2021 | $540.5M | 205.21% |
| FY2020 | $177.1M | 77.04% |
| FY2019 | $100.0M | (5.64%) |
| FY2018 | $106.0M | 5.76% |
| FY2017 | $100.2M | (1.03%) |
| FY2016 | $101.3M | 51.51% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $378.8M | 0.15% |
| Jun 2026 | $378.3M | 10.53% |
| Mar 2026 | $342.2M | 0.10% |
| Dec 2025 | $341.9M | 0.12% |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| OPK OPKO Health, Inc. compare | $462.7M |
| NEO NeoGenomics, Inc. | $378.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| WGS GeneDx Holdings Corp. compare | $96.8M |
| PSNL Personalis, Inc. compare | $39.2M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| CSTL Castle Biosciences, Inc. compare | $4.2M |
| FRNM Freenome, Inc compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement